Dr. Carmen B. Lozzio MD, FACMG has a distinguished career in genetics research, including extensive study of the K-562 cell line.
UT Graduate School of Medicine
UTRF Executes Licensing Agreement with CytoSen
The University of Tennessee Research Foundation (UTRF) has entered into a licensing agreement with CytoSen Therapeutics, Inc. for commercial rights to use the K-562 cell lines to produce an innovative natural killer (NK) cell therapy that harnesses the power of a person’s own immune cells to help fight cancer. Unlike other cell therapies, this approach has the potential to be used as a treatment component for many types of cancer.
UTRF Tech Talks: Technology Transfer at UTGSM
Presentation slides (pdf) UTRF Assistant Vice President of Licensing, Dr. Maha Krishnamurthy, spoke to UTGSM faculty, staff, and students about the technology transfer process and how it benefits the University. Dr. Krishnamurthy described the criteria UTRF uses in evaluating invention disclosures and explained how to submit an invention disclosure through the online IDEA portal. There was also a discussion about the (read more)